company background image
82P logo

Pacira BioSciences DB:82P Stock Report

Last Price

€18.20

Market Cap

€863.8m

7D

-1.1%

1Y

-40.5%

Updated

26 Dec, 2024

Data

Company Financials +

82P Stock Overview

Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. More details

82P fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Pacira BioSciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pacira BioSciences
Historical stock prices
Current Share PriceUS$18.20
52 Week HighUS$32.20
52 Week LowUS$10.70
Beta0.80
1 Month Change15.19%
3 Month Change43.31%
1 Year Change-40.52%
3 Year Change-66.61%
5 Year Change-54.73%
Change since IPO280.83%

Recent News & Updates

Recent updates

Shareholder Returns

82PDE PharmaceuticalsDE Market
7D-1.1%-0.3%-0.3%
1Y-40.5%-17.0%7.0%

Return vs Industry: 82P underperformed the German Pharmaceuticals industry which returned -17% over the past year.

Return vs Market: 82P underperformed the German Market which returned 7% over the past year.

Price Volatility

Is 82P's price volatile compared to industry and market?
82P volatility
82P Average Weekly Movement6.2%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 82P has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 82P's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006712Frank Leewww.pacira.com

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.

Pacira BioSciences, Inc. Fundamentals Summary

How do Pacira BioSciences's earnings and revenue compare to its market cap?
82P fundamental statistics
Market cap€863.75m
Earnings (TTM)-€87.17m
Revenue (TTM)€667.71m

1.3x

P/S Ratio

-9.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
82P income statement (TTM)
RevenueUS$694.96m
Cost of RevenueUS$255.38m
Gross ProfitUS$439.58m
Other ExpensesUS$530.31m
Earnings-US$90.73m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.97
Gross Margin63.25%
Net Profit Margin-13.06%
Debt/Equity Ratio78.4%

How did 82P perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:46
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pacira BioSciences, Inc. is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Balaji PrasadBarclays
Anita DushyanthBerenberg